CN102961448B - Composition capable of preventing and treating premature ovarian failure and preparation method thereof - Google Patents
Composition capable of preventing and treating premature ovarian failure and preparation method thereof Download PDFInfo
- Publication number
- CN102961448B CN102961448B CN201210551452.XA CN201210551452A CN102961448B CN 102961448 B CN102961448 B CN 102961448B CN 201210551452 A CN201210551452 A CN 201210551452A CN 102961448 B CN102961448 B CN 102961448B
- Authority
- CN
- China
- Prior art keywords
- parts
- ovarian failure
- premature ovarian
- add
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition capable of preventing and treating premature ovarian failure and a preparation method thereof. The composition is prepared from the following raw materials in parts by weight: 20-50 parts of glossy privet fruit, 30-50 parts of herba ecliptae and 10-60 parts of chicken kidney. According to the pathogenesis of the premature ovarian failure, Chinese herbal formulas selected through a lot of experiments are treated on the basis of syndrome differentiation under the guidance of the theory of traditional Chinese medicines; the experimental result shows that the composition provided by the invention can be used for obviously improving the developing follicle number, the mature follicle number and the corpus luteum number of mice in premature ovarian failure, improving the E2 level of serum and inhibit the expression of ovarian PI3K and akt of mice in premature ovarian failure; better resistance to premature ovarian failure than erzhi pills is displayed; and no reaction is discovered during the experimental process so that the clinical application is safe.
Description
Technical field
The present invention relates to a kind of compositions, be specifically related to a kind of composition and method of making the same and application with the effect of control premature ovarian failure.
Background technology
Premature ovarian failure refer to women before 40 years old because follicle in ovary is exhausted or iatrogenic injury causes ovarian function failure, take low estrogen and High gonadotropic hormone as feature, and Study of Etiology finds that this is sick closely related with autoimmune, chromosomal abnormality, promoting sexual gland hormone and receptor abnormality, lonizing radiation etc.In prior art, treat the hormone medicine that premature ovarian failure is conventional, untoward reaction is larger, and the traditional Chinese medical science has unique advantage in treatment aspect premature ovarian failure, thinks that this disease be take to suffer from a deficiency of the kidney as main, and stagnation of liver-QI, insufficiency of the spleen, disorder of QI and blood are also this sick the important pathogenesis.
At present, still do not have data to show that the Chinese medicine composition of ERZHI WAN and Chicken kidney is used for the treatment of premature ovarian failure clinically; Therefore, necessary developing on the basis of existing technology a kind ofly has better control premature ovarian failure effect, and the low Chinese medicine composition of untoward reaction.
Summary of the invention
Goal of the invention: the object of the invention is in order to solve the deficiencies in the prior art, a kind of compositions with the effect of control premature ovarian failure is provided, another object of the present invention is to provide the preparation method with control premature ovarian failure effect preparation.
Technical scheme: in order to realize above object, the technical scheme that the present invention takes is:
A compositions with the effect of control premature ovarian failure, it is to be made by the raw material of following parts by weight:
20 ~ 50 parts of Fructus Ligustri Lucidi, 30 ~ 50 parts of Herba Ecliptaes, 10 ~ 60 parts of Chicken kidney.
As preferred version, the above-described compositions with the effect of control premature ovarian failure, it is to be made by the raw material of following parts by weight:
30 ~ 40 parts of Fructus Ligustri Lucidi, 30 ~ 40 parts of Herba Ecliptaes, 20 ~ 40 parts of Chicken kidney.
The preparation method with control premature ovarian failure effect preparation provided by the invention, it comprises the following steps:
(1) ratio is got Herba Ecliptae by weight, adds the water of 6 to 12 times of weight, decocts 1 to 3 time, each 1 to 2 hour, collecting decoction, filtered, concentrated, in concentrated solution, add ethanol and make the concentration of ethanol reach 60% ~ 65%, standing 24 hours, filter, get supernatant, be evaporated to thick paste, vacuum drying, obtains Herba Ecliptae extract;
(2) get the Herba Ecliptae extract that step (1) prepares, in Fructus Ligustri Lucidi, Chicken kidney mix homogeneously, be ground into fine powder;
(3) get the medicine that fine powder that step (2) prepares and pharmaceutically acceptable carrier are prepared into pill, granule, capsule or Tabules.
The present invention adds carrier lactose or corn starch effective ingredient fine powder when making tablet, adds magnesium stearate lubricant while needing, mix homogeneously, and then tabletting is made tablet.When making capsule, effective ingredient fine powder is added to carrier lactose or corn starch mix homogeneously, granulate, the then encapsulated capsule of making.The present invention is when granulation agent, and effective ingredient fine powder and diluent lactose or corn starch mix homogeneously, granulate, is dried granulation agent.
As preferred version, the above-described compositions with the effect of control premature ovarian failure is prevented and treated the application in premature ovarian failure medicine in preparation.
Beneficial effect: compared to the prior art the compositions with the effect of control premature ovarian failure provided by the invention has the following advantages:
(1) compositions with the effect of control premature ovarian failure provided by the invention, according to the pathogenesis of premature ovarian failure, under the guidance of Chinese medical theory, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is screened Chinese prescription by great many of experiments, experimental result shows, compositions provided by the invention, can obviously improve follicle number in the growth of premature ovarian failure mice, mature follicle number and corpus luteum number, improve serum E2 level, and can suppress the ovary PI3K of premature ovarian failure mice and the expression of akt, demonstrated than the effect of the better anti-premature ovarian failure of ERZHI WAN (Fructus Ligustri Lucidi and Herba Ecliptae), and in experimentation, do not find untoward reaction, clinical practice safety.
(2) compositions with the effect of control premature ovarian failure provided by the invention, can facilitate and pharmaceutical carriers is prepared into multiple dosage form, clinically taking convenience, and experimental result shows compositions provided by the invention, curative effect is reliable, uses safety, and long-term taking has no side effect.
The specific embodiment
According to following embodiment, the present invention may be better understood.Yet, those skilled in the art will readily understand, the described concrete material proportion of embodiment, process conditions and result thereof be only for the present invention is described, and should also can not limit the present invention described in detail in claims.
Embodiment 1
A compositions 1, with the effect of control premature ovarian failure, it is to be made by the raw material of following parts by weight:
50 parts of Fructus Ligustri Lucidi, 50 parts of Herba Ecliptaes, 40 parts of Chicken kidney.
The preparation method 2, with control premature ovarian failure effect preparation, it comprises the following steps:
(1) get 50 parts of Herba Ecliptaes, add the water of 12 times of weight, decoct 3 times, each 2 hours, collecting decoction, filtered, be concentrated into relative density 1.10 left and right, in concentrated solution, add ethanol and make the concentration of ethanol reach 60%, standing 24 hours, filter, get supernatant, be evaporated to thick paste, vacuum drying, obtains Herba Ecliptae extract;
(2) get the Herba Ecliptae extract that step (1) prepares, add 50 parts of Fructus Ligustri Lucidi, 40 parts of mix homogeneously of Chicken kidney, be ground into fine powder;
(3) getting fine powder that step (2) prepares, to add refined honey appropriate, thin up, and as binding agent, pill, dry, obtain.
Embodiment 2
A compositions 1, with the effect of control premature ovarian failure, it is to be made by the raw material of following parts by weight:
50 parts of Fructus Ligustri Lucidi, 50 parts of Herba Ecliptaes, 50 parts of Chicken kidney.
The preparation method 2, with control premature ovarian failure effect preparation, it comprises the following steps:
(1) get 50 parts of Herba Ecliptaes, add the water of 10 times of weight, decoct 2 times, each 3 hours, collecting decoction, filtered, be concentrated into relative density 1.10 left and right, in concentrated solution, add ethanol and make the concentration of ethanol reach 60%, standing 24 hours, filter, get supernatant, be evaporated to thick paste, vacuum drying, obtains Herba Ecliptae extract;
(2) get the Herba Ecliptae extract that step (1) prepares, add 50 parts of Fructus Ligustri Lucidi, 50 parts of mix homogeneously of Chicken kidney, be ground into fine powder;
(3) get the fine powder that step (2) prepares, add 60% appropriate amount of ethanol, as binding agent, granulate, dry, granulate, tabletting, obtains tablet.
Embodiment 3
A compositions 1, with the effect of control premature ovarian failure, it is to be made by the raw material of following parts by weight:
20 parts of Fructus Ligustri Lucidi, 30 parts of Herba Ecliptaes, 10 parts of Chicken kidney.
The preparation method 2, with control premature ovarian failure effect preparation, it comprises the following steps:
(1) get 30 parts of Herba Ecliptaes, add the water of 10 times of weight, decoct 2 times, each 2 hours, collecting decoction, filtered, be concentrated into relative density 1.10 left and right, in concentrated solution, add ethanol and make the concentration of ethanol reach 60%, standing 24 hours, filter, get supernatant, be evaporated to thick paste, vacuum drying, obtains Herba Ecliptae extract;
(2) get the Herba Ecliptae extract that step (1) prepares, add 20 parts of Fructus Ligustri Lucidi, 10 parts of mix homogeneously of Chicken kidney, be ground into fine powder;
(3) get the fine powder that step (2) prepares, add 60% appropriate amount of ethanol, as binding agent, granulate, dry, granulate, obtains granule.
Embodiment 4
A compositions 1, with the effect of control premature ovarian failure, it is to be made by the raw material of following parts by weight:
30 parts of Fructus Ligustri Lucidi, 30 parts of Herba Ecliptaes, 20 parts of Chicken kidney.
The preparation method 2, with control premature ovarian failure effect preparation, it comprises the following steps:
(1) get 30 parts of Herba Ecliptaes, add the water of 12 times of weight, decoct 2 times, each 1 hour, collecting decoction, filtered, be concentrated into relative density 1.10 left and right, in concentrated solution, add ethanol and make the concentration of ethanol reach 60%, standing 24 hours, filter, get supernatant, be evaporated to thick paste, vacuum drying, obtains Herba Ecliptae extract;
(2) get the Herba Ecliptae extract that step (1) prepares, add 30 parts of Fructus Ligustri Lucidi, 20 parts of mix homogeneously of Chicken kidney, be ground into fine powder;
(3) get the fine powder that step (2) prepares, add 60% appropriate amount of ethanol, as binding agent, granulate, dry, granulate, the encapsulated capsule of making.
Embodiment 5 pharmacological experiments
1 experiment material
1.1 medicines and reagent: estradiol valerate tablet, Bayer medicines and health protection Guangzhou Branch; E2 detection kit, U.S. R & D company; PI3K, akt antibody is purchased from Bioworld; Tested medicine: the embodiment of the present invention 1 is prepared the pill of gained, ERZHI WAN (steaming 50 parts of Fructus Ligustri Lucidi, 50 parts of Herba Ecliptaes) is provided by preparation portion of Jiangsu TCM Hospital.
1.2 laboratory animals: Balb/c mice, female, Ai Ermaite Science and Technology Ltd. provides by Suzhou Industrial Park, animal credit number: SCXK (Soviet Union) 2009-0001.
1.3 instruments: TP1020 automatic dehydrator and RM2235 type paraffin slicing machine are German LEICA company product; The roasting sheet machine of CS-VI type stand sheet: Hubei Xiaogan great achievement medical apparatus company limited; Tissue-TekTEL organization embedding center, Japanese SAKURA company product; LEICADM1000 optical microscope, German Leica company product; Water isolation type electro-heating standing-temperature cultivator: Shanghai City leap medical apparatus and instruments one factory; Microwave oven, TCL company limited; MiniSee image capturing system.
2, experimental technique:
2.1 each experimental group causes the impact of premature ovarian failure mice on radiation
Get 60 of Balb/c female mices, age in 6-8 week, adaptability was raised after 1 week, was divided at random 5 groups, the compositions (5.9g/kg) that Normal group, model group, estradiol valerate group (0.015mg/kg), ERZHI WAN group (7.8g/kg) and the embodiment of the present invention 1 prepare.Except Normal group, all the other are respectively organized mice and all adopt
60the modeling of Co radiation gamma, irradiation total amount is 0.5Gy, accumulated dose is 0.5Gy, exposure rate 60cGy/min, irradiation field 20cm * 20cm apart from 80cm, raises after irradiation under without special former (SPF) level condition of causing a disease.Second day after irradiating, each organize mice respectively gavage give relative medicine, every day 1 time, totally 28 days.Normal group and model group give equal-volume distilled water (10ml/kg).1h after last administration, each is organized mouse orbit rear vein beard and gets blood, centrifugal, gets serum and surveys estradiol level.Get part ovary simultaneously and fix, routine is drawn materials, dehydration, and paraffin embedding, film-making, dyeing, mounting is read sheet under optical microscope, the quantity of various follicles and corpus luteum in counting ovary; The immunohistochemistry that is fixed for part ovary detects ovary PI3K and expresses.
2.2 serum E2 level determinations
Serum E2 level determination adopts ELISA method, and assay method is in strict accordance with test kit description.
2.3 ovary PI3K and akt detection of expression
Adopt ImmunohistochemistryMethods Methods rating model mouse ovarian PI3K and akt to express.Mice is put to death after getting blood, takes out ovary, isolated adipose tissue as far as possible, and by neutral formalin fixedly after 24h, dehydration of alcohol step by step, dimethylbenzene is transparent, waxdip, paraffin embedding, conventional section 4 μ m, drag for sheet in 45 ℃ of water-baths, and 80 ℃ of baking boxs are baked sheets, 40min.Adopting tachysynthesis group method to detect mouse ovarian PI3K expresses.Paraffin section de-waxing aquation, the middle-grade antigen retrieval of microwave 10 minutes.Natural cooling, rinses 3 times * 2min with PBS liquid (0.01mol/LPH7.4).The sealing of normal goats serum, incubated at room 10 minutes.The serum deprivation that inclines, does not wash, and drips antibody, hatches 1 hour for 37 ℃.PBS rinses, 2 minutes * 3 times.Drip instant tachysynthesis group MaxVisionTM bis-anti-, 37 ℃ or incubated at room 10 to 15 minutes.PBS rinses, 2 minutes * 3 times.Drip freshly prepared developer (DAB) 3 to 5 minutes, micro-Microscopic observation.Tap water fully rinses, and haematoxylin is redyed, and tap water rinses and returns indigo plant.Gradient alcohol dehydration, dimethylbenzene are transparent, neutral gum mounting.Immunohistochemical markers result: various protein positive cells be take endochylema after birth and are brown color as main, and feminine gender is not painted.
2.4 statistical procedures
Result adopts
represent, sample statistics analysis adopts independent sample t check.
3, experimental result:
3.1 compositionss provided by the invention cause the impact of premature ovarian failure mice ordinary circumstance on radiation
After all employings irradiation modelings, the equal lethargy of animal, activity obviously reduce, depilation, and weight loss is 2.0 ~ 4.0g approximately, but respectively organize mice all without dead, 1 week rear above-mentioned symptom of the gavage embodiment of the present invention 1 compositions takes a turn for the better gradually, and body weight increases gradually, and state restore normal growth.
3.2 compositionss provided by the invention and other each experimental group cause the impact of premature ovarian failure Mouse Ovary Tissues pathology on radiation, specific experiment is as shown in table 1:
Table 1 Chinese medicine composition on radiation cause premature ovarian failure Mouse Ovary Tissues pathology impact (
n=10)
Compare with Normal group,
#p<0.05,
##p<0.01; Compare with model group,
*p<0.05; With the comparison of ERZHI WAN group
Δp<0.05.
Experimental result by table 1 shows, in model group mice develop, follicle number, mature follicle number and corpus luteum number are compared obvious decline with normal group significant difference (P<0.01); Follicle number, mature follicle number and corpus luteum number and the model group (P<0.05 that significantly raises in each administration group mice develop; P<0.01).And experimental result shows that compositions group and ERZHI WAN group that the embodiment of the present invention 1 provides relatively have the effect of better promotion folliculus ovarii fully-developed, performance significantly increases follicle number, mature follicle number and corpus luteum number (P<0.05) in mice develop, shows to have after Fructus Ligustri Lucidi, Herba Ecliptae and Chicken kidney compatibility the effect of good Synergistic.
3.3 each group causes the impact of premature ovarian failure mice serum E2 level on radiation, specific experiment result is as shown in table 2:
Table 2 Chinese medicine composition on radiation cause premature ovarian failure mice serum E2 level impact (
n=10)
Compare with Normal group,
##, P<0.01; Compare with model group,
*p<0.05,
*p<0.01; With the comparison of ERZHI WAN group
Δp<0.05.
Experimental result by table 2 shows, compares with Normal group, and model group mice serum E2 level significantly reduces, and has significant difference (P<0.01).The compositions group mice serum E2 level that estradiol valerate group, ERZHI WAN group and the embodiment of the present invention 1 provide increases, and compares with model group, has significant difference (P<0.05; P<0.01).And experimental result shows, embodiment 1 compositions group mice serum E2 level provided by the invention is significantly higher than ERZHI WAN group (P<0.05), demonstrate the effect that stronger raising radiation causes premature ovarian failure mice serum E2 level, further demonstrated the effect of good Synergistic.
3.4 each groups cause the impact of premature ovarian failure mouse ovarian PI3K and akt expression on radiation, specific experiment result is as shown in table 3:
Table 3 Chinese medicine composition on radiation cause the impact that premature ovarian failure mouse ovarian PI3K and akt express (
n=10)
Compare with Normal group,
##, P<0.01; Compare with model group,
*p<0.05,
*p<0.01; With the comparison of ERZHI WAN group
Δp<0.05.
PI3K/akt signal path plays an important role in follicular development in early days.Table 3 result shows, Normal group mouse ovarian PI3K and akt express all lower, are about 2% left and right,
60after Co irradiates, mouse ovarian PI3K and akt express and significantly increase, and reach respectively 11.9% and 17.3%.After ERZHI WAN and embodiment 1 compositions group administration, all significantly reduce PI3K and the akt of model mice ovary high expressed, compare with model group, there is statistical significance (P<0.05, P<0.01), and experimental result show that compositions group and ERZHI WAN group that the embodiment of the present invention 1 provides relatively have stronger inhibition
60co irradiates the activation of the mouse ovarian PI3K/akt signal path causing, thereby suppresses a large amount of activation of follicle.
By above-mentioned experimental result, shown, the compositions with the effect of control premature ovarian failure provided by the invention, can obviously improve follicle number, mature follicle number and corpus luteum number in the growth of premature ovarian failure mice, improve serum E2 level, and can suppress the ovary PI3K of premature ovarian failure mice and the expression of akt, demonstrated than the effect of the better anti-premature ovarian failure of ERZHI WAN (Fructus Ligustri Lucidi and Herba Ecliptae), there is better clinical efficacy, and drug safety.
Above embodiment is only explanation technical conceive of the present invention and feature; its object is to allow person skilled in the art understand content of the present invention and implemented; can not limit the scope of the invention with this; all equivalences that spirit is done according to the present invention change or modify, and all should be encompassed in protection scope of the present invention.
Claims (2)
1. a compositions with the effect of control premature ovarian failure, is characterized in that, it is to be made by the raw material of following parts by weight:
50 parts of Fructus Ligustri Lucidi, 50 parts of Herba Ecliptaes, 40 parts of Chicken kidney;
Preparation process comprises:
(1) get 50 parts of Herba Ecliptaes, add the water of 12 times of weight, decoct 3 times, each 2 hours, collecting decoction, filtered, be concentrated into relative density 1.10, in concentrated solution, add ethanol and make the concentration of ethanol reach 60%, standing 24 hours, filter, get supernatant, be evaporated to thick paste, vacuum drying, obtains Herba Ecliptae extract;
(2) get the Herba Ecliptae extract that step (1) prepares, add 50 parts of Fructus Ligustri Lucidi, 40 parts of mix homogeneously of Chicken kidney, be ground into fine powder;
(3) getting fine powder that step (2) prepares, to add refined honey appropriate, thin up, and as binding agent, pill, dry, obtain.
2. the compositions with the effect of control premature ovarian failure claimed in claim 1 is prevented and treated the application in premature ovarian failure medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210551452.XA CN102961448B (en) | 2012-12-18 | 2012-12-18 | Composition capable of preventing and treating premature ovarian failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210551452.XA CN102961448B (en) | 2012-12-18 | 2012-12-18 | Composition capable of preventing and treating premature ovarian failure and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102961448A CN102961448A (en) | 2013-03-13 |
| CN102961448B true CN102961448B (en) | 2014-04-30 |
Family
ID=47792067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210551452.XA Expired - Fee Related CN102961448B (en) | 2012-12-18 | 2012-12-18 | Composition capable of preventing and treating premature ovarian failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961448B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1192915A (en) * | 1997-03-12 | 1998-09-16 | 龙恩明 | Rendu tonic wine |
| CN101628101A (en) * | 2009-05-13 | 2010-01-20 | 九芝堂股份有限公司 | Medicine combination and application thereof in preparing preparations for treating premature ovarian failure |
| CN101850016A (en) * | 2009-03-31 | 2010-10-06 | 江苏康缘药业股份有限公司 | Chinese medicinal composition for treating premature ovarian failure and preparation method thereof |
| CN101961419A (en) * | 2010-09-13 | 2011-02-02 | 南京中医药大学 | Health-care product for preventing and treating premature ovarian failure and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY159181A (en) * | 2006-11-21 | 2016-12-30 | Univ Putra Malaysia | Use of an anti-cancer compound |
-
2012
- 2012-12-18 CN CN201210551452.XA patent/CN102961448B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1192915A (en) * | 1997-03-12 | 1998-09-16 | 龙恩明 | Rendu tonic wine |
| CN101850016A (en) * | 2009-03-31 | 2010-10-06 | 江苏康缘药业股份有限公司 | Chinese medicinal composition for treating premature ovarian failure and preparation method thereof |
| CN101628101A (en) * | 2009-05-13 | 2010-01-20 | 九芝堂股份有限公司 | Medicine combination and application thereof in preparing preparations for treating premature ovarian failure |
| CN101961419A (en) * | 2010-09-13 | 2011-02-02 | 南京中医药大学 | Health-care product for preventing and treating premature ovarian failure and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| Er Zhi Wan, an ancient herbal decoction for woman menopausal syndrome, activates the estrogenic response in cultured MCF-7 cells: An evaluation of compatibility in defining the optimized preparation method;Hong Xu et al;《Journal of Ethnopharmacology》;20120616;第143卷;第109–115页,尤其是第109页摘要部分，第113页右栏第3段 * |
| Hong Xu et al.Er Zhi Wan, an ancient herbal decoction for woman menopausal syndrome, activates the estrogenic response in cultured MCF-7 cells: An evaluation of compatibility in defining the optimized preparation method.《Journal of Ethnopharmacology》.2012,第143卷 |
| JP特开2010-510207A 2010.04.02 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102961448A (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110059124A1 (en) | The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion | |
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| CN103190621A (en) | Propolis soft capsule and preparation method thereof | |
| CN103705754B (en) | A kind of Chinese medicine composition of systemic lupus erythematosus | |
| CN103028065B (en) | Preparation containing herba violae, rhizoma cyperi and herba leonuri and preparation method and detection method thereof | |
| CN108143825B (en) | Medicine for treating psoriasis, preparation method and detection method thereof | |
| Long et al. | Flavonoid of Drynaria fortunei protects against acute renal failure | |
| CN102058822B (en) | Pharmaceutical composition for strengthening stomach and promoting digestion | |
| CN102961448B (en) | Composition capable of preventing and treating premature ovarian failure and preparation method thereof | |
| CN114767706B (en) | Application of polygonatum odoratum polysaccharide in preparation of medicine for treating asthma | |
| CN101011543B (en) | Antineoplastic medicine composition | |
| CN114869952A (en) | Application of cortex lycii radicis extract in preparation of product for repairing reproductive system injury | |
| CN104814944A (en) | Transdermal patch for preventing and treating lumbar disc herniation and preparation method thereof | |
| CN1923268B (en) | Medicinal composition for treating rhinitis, its preparing method and quality controlling means | |
| CN1969937B (en) | Pharmaceutical composition for treating hepatitis | |
| CN104547514A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof | |
| CN109700801A (en) | A kind of pharmaceutical composition for treating psoriasis | |
| CN100368004C (en) | Chinese medicinal composition for treating psoriasis, its preparation and quality control | |
| CN111643641B (en) | Food therapy formula for clearing heat, invigorating spleen and tonifying kidney and preparation method and application thereof | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof | |
| CN103566276B (en) | A kind of Tibetan medicinal composition being used for the treatment of gastropathy and preparation method thereof | |
| CN1961895B (en) | A novel anticancer pharmaceutical composition and preparation method thereof | |
| CN102727729A (en) | Decoction for treating eye disease | |
| CN102764314A (en) | Traditional Chinese medicine compound Lianweng dysentery-inhibiting granules for curing white scour of piglets, preparation method and application thereof | |
| CN103381205B (en) | Centipede pseudo-ginseng extract product is at the application prepared in medicine against intestinal adhesion and medicine thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140430 Termination date: 20141218 |
|
| EXPY | Termination of patent right or utility model |